Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × Triamcinolone Acetonide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uveal Melanoma 2 Lymphoma, T-Cell, Cutaneous 2 Lichen Planus, Oral 2 Stomach Neoplasms 1 Retinal Diseases 1 Recurrence 1 Radiodermatitis 1 Pancreatitis, Chronic 1 Pancreatic Neoplasms 1 Pain 1 Neuroma, Acoustic 1 Mycosis Fungoides 1 Melanoma 1 Macular Degeneration 1 Lymphomatoid Papulosis 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Leiomyoma 1 Glioblastoma 1 Fibroma 1 Exanthema 1 Esophageal Stenosis Acquired 1 Dupuytren Contracture 1 Disease 1 Dermatitis, Contact 1 Choroid Diseases 1 Chalazion 1 Castration Resistant Prostate Cancer 1

Interventions

Carboplatin 345 Cisplatin 240 Paclitaxel 208 Radiotherapy 205 Pemetrexed 190 Docetaxel 170 Gemcitabine 157 pembrolizumab 146 Erlotinib Hydrochloride 111 Magnetic Resonance Spectroscopy 99 Etoposide 98 Bevacizumab 96 Specimen Handling 81 Nivolumab 75 Radiosurgery 73 durvalumab 72 Blood Specimen Collection 65 Drug Therapy 60 osimertinib 56 Vinorelbine 54 Gefitinib 50 Surveys and Questionnaires 47 atezolizumab 44 Biopsy 43 Irinotecan 42 Radiation 41 Topotecan 39 Standard of Care 38 Cyclophosphamide 38 Surgical Procedures, Operative 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡